Literature DB >> 1324789

Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis.

L Ferradini1, S Roman-Roman, J Azocar, M F Avril, S Viel, F Triebel, T Hercend.   

Abstract

Multiple experimental and clinical studies have suggested that the immune system may, to some extent, control the development of melanomas. The presence of tumor-infiltrating lymphocytes could reflect an in situ immune reaction directed to the malignant cells. The characterization of T-cell receptor (TCR) expressed by tumor-infiltrating lymphocytes is one way to precisely analyze these local T-cell responses. In this study, we have assessed the TCR alpha/beta variability in tumor-infiltrating lymphocytes from a subcutaneous metastasis of a melanoma patient. Using the anchored-polymerase chain reaction 268 TCR alpha and 266 TCR beta chain transcripts have been cloned and sequenced. Their analysis shows that the T-cell infiltrate is extremely diverse, with no preferential TCR gene segment usage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324789

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 2.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

Authors:  P thor Straten; J C Becker; T Seremet; E B Bröcker; J Zeuthen
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Oligoclonality of CD8+ T cells in breast cancer patients.

Authors:  K Ito; J Fetten; H Khalili; S Hajdu; E Busch; R Pergolizzi; V Vinciguerra; M D Chang
Journal:  Mol Med       Date:  1997-12       Impact factor: 6.354

5.  Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.

Authors:  T Ramirez-Montagut; D M Andrews; A Ihara; S Pervaiz; F Pandolfi; P J Van Den Elsen; R Waitkus; L A Boyle; M Hishii; J T Kurnick
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

6.  T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer.

Authors:  M R Zocchi; M Ferrarini; N Migone; G Casorati
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

7.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

8.  Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.

Authors:  Amanda L Boehm; Jack Higgins; Alex Franzusoff; Jeffrey Schlom; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

9.  T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.

Authors:  J Shilyansky; M I Nishimura; J R Yannelli; Y Kawakami; L S Jacknin; P Charmley; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

Authors:  M Sensi; C Traversari; M Radrizzani; S Salvi; C Maccalli; R Mortarini; L Rivoltini; C Farina; G Nicolini; T Wölfel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.